Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Rozanolixzumab and Batoclimab Effectiveness: Rozanolixzumab at doses of 7mg/kg and 10mg/kg showed superior effectiveness in improving MG-ADL scores compared to belimumab, efgartigimod (vyvgart), mezagitamab, and nipocalimab, with mean differences ranging from 2 to 3.69. Batoclimab at doses of 340mg and 680mg was more effective in improving QMG scores than placebo and other monoclonal antibodies, except rozanolixzumab, with mean differences ranging from 4.32 to 9.31.
• Efgartigimod Comparison: Efgartigimod (vyvgart) was less effective than rozanolixzumab in improving MG-ADL scores, with other monoclonal antibodies like belimumab, mezagitamab, and nipocalimab also showing lower effectiveness compared to rozanolixzumab.
• Belimumab demonstrated the most favorable safety profile with a significantly lower risk of adverse events compared to rozanolixzumab 7mg/kg (RR (Relative risk) 0.08, 95% CrI 0.01 to 0.94) and rozanolixzumab 10mg/kg (RR 0.08, 95% CrI 0.01 to 0.86).
• Rozanolixzumab was associated with a higher incidence of adverse events compared to belimumab, but specific adverse effects or comparative data for efgartigimod (vyvgart) were not detailed in the study.
• There is no population types or subgroups information available in the reviewed studies.